Company Overview of Intersect ENT, Inc.
Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November, 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
1555 Adams Drive
Menlo Park, CA 94025
Founded in 2003
Key Executives for Intersect ENT, Inc.
Chief Executive Officer
Total Annual Compensation: $334.8K
Chief Operating Officer and Senior Vice President
Total Annual Compensation: $293.2K
Vice President of Sales
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2013.
Intersect ENT, Inc. Key Developments
Intersect ENT, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Year Ended December 31, 2014
Jan 12 15
Intersect ENT, Inc. announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company expected to report revenue in the range of $13.2 to $13.4 million, an increase of approximately 91% over the fourth quarter of 2013.
For the year end, the company expects to report revenue in the range of $38.4 to $38.6 million.
Intersect ENT, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM
Dec 18 14
Intersect ENT, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer, President and Director.
Intersect ENT, Inc. Announces Board Changes, Effective December 15, 2014
Dec 10 14
On December 8, 2014, Rick D. Anderson tendered his resignation as a member of the Board of Directors of Intersect ENT, Inc., as a member of the Audit Committee of the Board, and as a member and the chairperson of the Nominating and Corporate Governance Committee of the Board, effective December 15, 2014. On December 9, 2014, the Board appointed Frederic H. Moll as a member of the Audit Committee of the Board to fill the vacancy created by Mr. Anderson's resignation. On December 8, 2014, Mark Fletcher tendered his resignation as a member of the Board of Intersect, effective December 15, 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|